Drug Profile
Calcitonin injection - Novartis
Alternative Names: Miacalcic Injection; Salcatonin injection - NovartisLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Novartis
- Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
- Mechanism of Action Calcitonin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Malignant hypercalcaemia; Osteitis deformans; Postmenopausal osteoporosis
Most Recent Events
- 20 Jul 2012 The European Medicines Agency recommended that due to an increased risk of cancer associated with long-term use, calcitonin medicines should only be used for the shortest possible time using the minimum effective dose .
- 03 Dec 2002 The CPMP has recommended approval of injectable calcitonin for prevention of acute bone loss due to sudden immobilisation throughout the European Union
- 13 Nov 2000 Launched for Postmenopausal osteoporosis in Germany (Injection)